Domain Therapeutics
Domain Therapeutics develops small molecules targeting G-coupled protein receptors.
Total raised
€46M
€45,873,128
Funding rounds
2
Investors
10
distinct backers
Active since
2020-01
latest 2022-05
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood36
base rate 44% for Series A
- ▼ Overdue vs cohort gap
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood16
base rate 12% (2+ rounds)
- ▲ €30M+ raised
- ▲ 25y since founding
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-05-10 | Series A | €40M | 3B Future Health Fund,adMare BioInnovations,CTI Life Sciences,Omnes Capital,Panacea Venture,Schroders Capital+4 more | View deal → |
| 2020-01-13 | Other | €6.0M | — | View deal → |
Investors
10Related news
- Domain Therapeutics Raises $42M in Series A Financingfinsmes.com · 2022-05
- finsmes.com
Similar companies
same sector or country- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Mistral AI€3.5BFrance · AI
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- ContentSquare€1.3BFrance · Software